Comparative Pharmacology
Head-to-head clinical analysis: ETHCHLORVYNOL versus SONATA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHCHLORVYNOL versus SONATA.
ETHCHLORVYNOL vs SONATA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ethchlorvynol is a sedative-hypnotic with central nervous system depressant effects. Its exact mechanism is unknown, but it may potentiate GABA activity or depress neuronal excitability.
Zaleplon is a non-benzodiazepine hypnotic that selectively binds to the benzodiazepine type 1 (BZ1) receptor subtype on the gamma-aminobutyric acid (GABA) A receptor complex, potentiating GABA-mediated chloride ion influx and neuronal inhibition.
500 mg to 1 g orally at bedtime as needed for insomnia.
10 mg orally at bedtime; range 5-20 mg; maximum 20 mg per day.
None Documented
None Documented
10-25 minutes (initial rapid distribution phase); terminal elimination half-life approximately 4-6 hours in adults (prolonged in liver disease due to reduced clearance).
Clinical Note
moderateEthchlorvynol + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluticasone propionate."
Clinical Note
moderateEthchlorvynol + Clemastine
"The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clemastine."
Clinical Note
moderateEthchlorvynol + Venlafaxine
"The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Venlafaxine."
Clinical Note
moderateTerminal elimination half-life is approximately 1 hour (range 0.7–1.7 h) in healthy adults; elderly patients and those with hepatic impairment may have prolonged half-life (up to 2–3 h).
Renal: <1% unchanged; Hepatic metabolism to inactive conjugates; Fecal: minimal. Approximately 90% of a dose is excreted in urine as glucuronide conjugates within 24 hours.
Approximately 83% of administered radioactivity is excreted in urine (with less than 1% as unchanged drug) and 17% in feces.
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic
Ethchlorvynol + Nefazodone
"The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nefazodone."